Jouvence Pharmaceuticals Inc.
This article was originally published in Start Up
Executive SummaryDrug Discovery Tools; Genomics. Jouvence is dedicated to developing anti-aging therapies through genomics efforts. The company has licensed the LAG-1 gene, one of the first genes definitively linked to the longevity of an organism. Yeast strains in which the gene has been knocked out live 100% longer than average.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.